These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35901082)

  • 21. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
    Dehury B; Raina V; Misra N; Suar M
    J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2.
    Celik I; Khan A; Dwivany FM; Fatimawali ; Wei DQ; Tallei TE
    Mol Divers; 2022 Dec; 26(6):3309-3324. PubMed ID: 35138508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
    Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
    J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption.
    Ren W; Lan J; Ju X; Gong M; Long Q; Zhu Z; Yu Y; Wu J; Zhong J; Zhang R; Fan S; Zhong G; Huang A; Wang X; Ding Q
    PLoS Pathog; 2021 Nov; 17(11):e1010053. PubMed ID: 34748603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico binding profile characterization of SARS-CoV-2 spike protein and its mutants bound to human ACE2 receptor.
    Zhang Y; He X; Zhai J; Ji B; Man VH; Wang J
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of nonsynonymous mutations in the spike protein of SARS-CoV-2 and its interaction with the ACE2 receptor by molecular docking and MM/GBSA approach.
    Aljindan RY; Al-Subaie AM; Al-Ohali AI; Kumar D T; Doss C GP; Kamaraj B
    Comput Biol Med; 2021 Aug; 135():104654. PubMed ID: 34346317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corilagin and 1,3,6-Tri-
    Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
    Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.
    Pourmand S; Zareei S; Shahlaei M; Moradi S
    Comput Biol Med; 2022 Jul; 146():105625. PubMed ID: 35688710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzimidazole compound abrogates SARS-COV-2 receptor-binding domain (RBD)/ACE2 interaction In vitro.
    Omotuyi O; Olatunji OM; Nash O; Oyinloye B; Soremekun O; Ijagbuji A; Fatumo S
    Microb Pathog; 2023 Mar; 176():105994. PubMed ID: 36682669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative study of receptor interactions between SARS-CoV and SARS-CoV-2 from molecular modeling.
    Lai HTT; Nguyen LH; Phan AD; Kranjc A; Nguyen TT; Nguyen-Manh D
    J Mol Model; 2022 Sep; 28(10):305. PubMed ID: 36074206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
    Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay.
    Mousa ZS; Abdulamir AS
    Arch Razi Inst; 2022 Feb; 77(1):391-402. PubMed ID: 35891753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations.
    Patel CN; Goswami D; Jaiswal DG; Parmar RM; Solanki HA; Pandya HA
    J Mol Graph Model; 2021 Jun; 105():107874. PubMed ID: 33647752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors.
    Singh R; Bhardwaj VK; Sharma J; Kumar D; Purohit R
    Comput Biol Med; 2021 Sep; 136():104631. PubMed ID: 34273770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Computational Approach to Evaluate the Combined Effect of SARS-CoV-2 RBD Mutations and ACE2 Receptor Genetic Variants on Infectivity: The COVID-19 Host-Pathogen Nexus.
    Ashoor D; Ben Khalaf N; Marzouq M; Jarjanazi H; Chlif S; Fathallah MD
    Front Cell Infect Microbiol; 2021; 11():707194. PubMed ID: 34434902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay.
    Xiang Y; Zhai G; Li Y; Wang M; Chen X; Wang R; Xie H; Zhang W; Ge G; Zhang Q; Xu Y; Caflisch A; Xu J; Chen H; Chen L
    Int J Biol Macromol; 2023 Jan; 226():780-792. PubMed ID: 36521705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.
    Demers-Mathieu V; DaPra C; Medo E
    Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.